Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary Bypass
Preclinical animal models used in this study showed that Ir-CPI is an effective and safe antithrombotic agent that provides a clinically relevant approach to thrombosis prevention in bypass systems, including highly thrombogenic CPB.
1 min read
